Hummingbird Diagnostics Gmbh

Comprehensive Biomarker Center Gmbh

Novaliq Gmbh

Dermaliq Therapeutics, Inc.

Codex Dna, Inc.

Synthetic Genomics, Inc.

Markus Beier

Andreas Keller

Eckart Meese

Anne Borries

Frank Löscher

Peer Friedrich Staehler

Anke Wendschlag

Petra Leidinger

Chiara Silvana Leo

Bernhard Günther

Hugo Katus

Ralf Grillenberger

Hartmut Voss

Sonja Krösser

Benjamin Meder

Matthias Scheffler

Jörg Haisser

Joachim Jaeger

Peer Friedrich Stähler

Jack Thacher Leonard

Patrick Küry

Raphael Carapito

Kirsten Eickhoff

Hans-Peter Hartung

Thomas Schlüter

Cord F Staehler

Joachim Jäger

Alice Meides

Wolfgang Rottbauer

Thomas Brefort

Jack T Leonard

Timour Prozorovski

Daniela Willen

Mustafa Kahraman

Peer F Stähler

Hugo A Katus

Jens Ingwersen

Orhan Aktas

Britta Vogel

Mark Matzas

Oliver Schlüter

Thomas Laufer

Cord F STÄHLER

Raphaël Carapito

Eckhart Meese

Anke Booker

Jochen Kohlhaas

Peer Stähler

Jorg Haisser

Sonja Krosser

Frank Loscher

Valesca Boisguerin

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w/v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

Ophthalmic composition for treatment of dry eye disease

The invention provides pharmaceutical compositions comprising cyclosporine dissolved in a semifluorinated alkane for use in the treatment of uveitis.

Ophthalmic composition for the treatment of uveitis

The present disclosure is in the field of ointments which can be useful for the treatment of diseases or conditions associated with lipid barrier damage of the skin. The ointment comprises a semifluorinated alkane and a solid thickening agent, e.g., a wax, a triglyceride, cetyl alcohol, cetyl palmitate, or tetradecanol.

Lipid barrier repair

The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.

Opthalmic compositions comprising F6H8

The present invention relates to a method of removing an RNA fraction with &#x2265;200 nucleotides in length from a whole blood sample. The present invention also relates to a method of purifying an RNA fraction with &#x3c;200 nucleotides in length from a whole blood sample. The present invention further relates to a method of determining the level of RNA molecules with &#x3c;200 nucleotides in length. In addition, the present invention relates to a method for diagnosing a disease in an individual. Moreover, the present invention relates to a kit which is useful for carrying out the methods of the present invention.

Purification of RNA fractions using a hydrophilic polymeric material

The present disclosure relates to topical sunscreen formulations comprising a semifluorinated alkane and a metal oxide selected from titanium dioxide, zinc oxide or mixtures thereof.

Topical sunscreen formulation

A pharmaceutical composition comprising a semifluorinated alkane of formula (I): F(CF2)(CH2)H, wherein n is an integer from 4 to 6, and m is an integer from 5 to 8, for use in the treatment or prevention of a disease or condition relating to an ocular surface of an eye of an individual, wherein the individual is a contact lens wearer, and wherein the contact lens is a hydro gel contact lens and the composition is administered topically to a surface of the eye of the individual before the contact lens is inserted to the eye of the individual and/or during contact lens wear and/or after the contact lens has been removed from the eye of the individual, or wherein the contact lens is a silicone hydrogel contact lens and the composition is administered topically to a surface of the eye of the individual after the contact lens has been removed from the eye of the individual.

Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions

The present invention relates to methods, kits and means for diagnosing Parkinson's disease in a blood sample from a subject. Further, the present invention relates to a set of polynucleotides for detecting sets of miRNAs for diagnosing Parkinson's disease in a blood sample from a subject.

miRNAs as non-invasive biomarkers for Parkinson's disease

The present invention relates to methods, kits and uses for diagnosing heart failure using miRNA-biomarker from blood.

Determination of miR-423-5p in heart failure

The invention relates to methods and devices for preparing synthetic nucleic acids.

Synthesis of sequence-verified nucleic acids

The present invention relates to methods, kits and uses for determining platelet-miRNAs in a from a platelet-comprising fraction derived from a whole blood sample from a subject affected or suspected to be affected by Alzheimer's Disease.

Determination of platelet-miRNAs in alzheimer's disease

The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of dilated cardiomyopathy in a body fluid sample from a subject.

Complex sets of miRNAs as non-invasive biomarkers for dilated cardiomyopathy

The present invention relates to methods of determining whether a patient responds to a therapeutic treatment of multiple sclerosis (MS), of monitoring the course of multiple sclerosis (MS) in a patient, of determining the risk for a relapse of multiple sclerosis (MS) in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient. Said methods are based on the determination of the level of at least one miRNA in a test sample isolated from the patient. The present invention also relates to a method of identifying a compound suitable for the treatment of multiple sclerosis in a patient. Further, the present invention relates to the use of a polynucleotide or a polynucleotide set for detecting a miRNA to determine whether a patient responds to a therapeutic treatment of multiple sclerosis, to monitor the course of multiple sclerosis in a patient, to determine the risk of a relapse of multiple sclerosis in a patient, to adjust the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient, and to identify a compound suitable for the treatment of multiple sclerosis in a patient. Furthermore, the present invention relates to a kit for determining whether a patient responds to a therapeutic treatment of multiple sclerosis, for monitoring the course of multiple sclerosis in a patient, for determining the risk of a relapse of multiple sclerosis in a patient, for adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient, or for identifying a compound suitable for the treatment of multiple sclerosis in a patient comprising means for determining the level of at least one miRNA in a test sample isolated from a patient.

MiRNA based treatment monitoring in multiple sclerosis

The present invention provides novel methods for diagnosing diseases based on the determination of specific miRNAs that have altered expression levels in disease states compared to healthy controls.

MiRNA fingerprint in the diagnosis of multiple sclerosis

The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.

miRNA in the diagnosis of ovarian cancer

Growing community of inventors

Weinheim, Germany

Markus Beier